MedPath

Can exercise prevent long-lasting pain and disability following a blunt injury to the chest?

Not Applicable
Completed
Conditions
Prevention of chronic pain and disability in patients with blunt chest wall trauma
Signs and Symptoms
Registration Number
ISRCTN65829737
Lead Sponsor
Swansea Bay University Health Board
Brief Summary

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35393332/ (added 09/01/2023)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
360
Inclusion Criteria

1. Presenting to hospital with a diagnosis of isolated blunt chest wall trauma (defined as any injury ranging from bruising to the chest wall to rib fractures with or without underlying injury to the lung, and no concurrent injuries that preclude completion of the exercise programme)
2. Aged 16 years or above
3. Able to either give informed consent independently, or with support of a family member/carer or translator
4. Able to either complete the exercise programme independently, or with support of a family member/carer
5. Able to complete surveys independently, or with support of a family member/carer or translator

Exclusion Criteria

1. Lacking sufficient capacity to provide informed consent or complete surveys. (Assistance from a family member/carer or translator is acceptable, if needed.)
2. Lacking sufficient capacity to complete the exercise programme either independently, or with the support of a family member/carer
3. Aged under 16 years
4. Presenting with immediately life-threatening injuries or any concurrent injury precluding participation in the intervention (patients with minor injuries not precluding participation, such as a concurrent knee ligament injury, will still be eligible)
5. Hospitalised prisoners

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Chronic pain is measured using the Brief Pain Inventory (short form) at baseline and 3 months follow-up<br>2. Disability is measured using the EQ5D-5L Survey at baseline and 3 months follow-up
Secondary Outcome Measures
NameTimeMethod
1. Cost-effectiveness measured using a cost-utility (incremental cost per QALY) analysis at 3 month follow-up<br>2. Safety measured using rate of adverse events and serious adverse events at 3-month follow-up<br>3. Acceptability of programme measured using five focus groups, one per participating site, in intervention group only at end of 3-month follow-up
© Copyright 2025. All Rights Reserved by MedPath